Axatilimab is under clinical development by Incyte and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axatilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Axatilimab overview
Axatilimab is (Niktimvo) act as antineoplastic agent. It is formulated as solution for intravenous route of administration. Niktimvo is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Axatilimab (SNDX-6352) is under development for the treatment of graft versus host disease, solid tumours including intrahepatic cholangiocarcinoma, human epidermal growth factor receptor 2 negative breast cancer, and idiopathic pulmonary fibrosis, polycythemia vera, chronic myelomonocytic leukemia (CMML), Myelodysplastic Syndrome, chronic myelocytic leukemia (CML, chronic myeloid leukemia), chronic idiopathic myelofibrosis (primary myelofibrosis), essential thrombocythemia. It is administered intravenously as solution for infusion. The drug candidate is a humanized IgG4 monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R).
It was under development for Coronavirus disease 2019 (COVID-19) and relapsed/refractory Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Incyte overview
Incyte is a biopharmaceutical company, that discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
For a complete picture of Axatilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
